Mirati Therapeutics, Inc. (NASDAQ:MRTX – Get Rating) Director Julie M. Cherrington sold 2,546 shares of the stock in a transaction that occurred on Wednesday, January 18th. The stock was sold at an average price of $44.66, for a total transaction of $113,704.36. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
Mirati Therapeutics Price Performance
Shares of Mirati Therapeutics stock opened at $45.66 on Monday. Mirati Therapeutics, Inc. has a fifty-two week low of $32.96 and a fifty-two week high of $124.81. The firm has a fifty day moving average price of $57.58 and a two-hundred day moving average price of $66.75. The company has a market cap of $2.63 billion, a PE ratio of -3.41 and a beta of 1.07.
Mirati Therapeutics (NASDAQ:MRTX – Get Rating) last released its quarterly earnings data on Tuesday, November 8th. The biotechnology company reported ($3.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.46) by $0.37. The company had revenue of $5.43 million for the quarter, compared to the consensus estimate of $4.72 million. Mirati Therapeutics had a negative return on equity of 60.40% and a negative net margin of 6,253.81%. Analysts expect that Mirati Therapeutics, Inc. will post -13.5 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Analyst Upgrades and Downgrades
Several equities analysts have issued reports on the company. B. Riley began coverage on Mirati Therapeutics in a report on Friday, October 28th. They set a “neutral” rating and a $72.00 price objective on the stock. Citigroup downgraded Mirati Therapeutics from a “buy” rating to a “neutral” rating and cut their target price for the stock from $121.00 to $53.00 in a research note on Friday, December 9th. StockNews.com upgraded Mirati Therapeutics to a “sell” rating in a report on Friday, January 13th. Needham & Company LLC assumed coverage on Mirati Therapeutics in a report on Wednesday, December 14th. They set a “hold” rating on the stock. Finally, Barclays decreased their price objective on Mirati Therapeutics from $169.00 to $90.00 in a report on Wednesday, December 14th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, Mirati Therapeutics currently has an average rating of “Hold” and an average price target of $83.20.
Mirati Therapeutics Company Profile
Mirati Therapeutics, Inc, a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development.
- Get a free copy of the StockNews.com research report on Mirati Therapeutics (MRTX)
- CVS Health is Growing into an Integrated Healthcare Organization
- Is C3.ai Stock a ChatGPT Artificial Intelligence Play?
- NVIDIA Outlook Improving: Watchlist Candidate for 2023
- Which Wireless Stock Should You Buy in 2023?
- Is Virgin Galactic Stock Preparing for Lift-Off?
Receive News & Ratings for Mirati Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.